Company Profile
Exicure Stock Price, News & Catalysts
- Ticker:
- XCUR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.15 USD (-11.54%)
Close
Last updated: August 21, 2026
19.8M USD
Market cap
Why the stock is moving
As of Aug 21, 2026, XCUR closed down 11.5% at $1.15. No new same-company headline was identified in the current news window.
Company overview
Early-Stage Biopharmaceutical Operations
Exicure is rebuilding a research and development business following the acquisition of GPCR Therapeutics USA. The company has limited liquidity and is simultaneously evaluating financing and strategic alternatives.
Stem-Cell Mobilization Program
Its lead development program is being evaluated for improving stem-cell mobilization in multiple myeloma and sickle cell disease and for supporting cell and gene therapy procedures. The source disclosure does not provide a named candidate or development timetable.
Future catalysts
- Exicure is largely a legacy and closeout story, so the catalysts are any strategic or asset-resolution update rather than a live development milestone. The market is focused on what remains.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Exicure (XCUR)?
Exicure (XCUR) most recently closed at 1.15 USD, a -11.54% move versus the previous session.
What is the market cap of Exicure (XCUR)?
Exicure currently has a market capitalization of 19.8M USD on BioPharmSignal.
What does Exicure do?
Early-Stage Biopharmaceutical Operations Exicure is rebuilding a research and development business following the acquisition of GPCR Therapeutics USA. The company has limited liquidity and is simultaneously evaluating financing and strategic alternatives. Stem-Cell Mobilization Program Its lead development program is being evaluated for improving stem-cell...
On which exchange is XCUR stock listed?
Exicure (XCUR) is associated with NASDAQ, United States, Biopharma.
What is Early-Stage?
Early-Stage Biopharmaceutical Operations Exicure is rebuilding a research and development business following the acquisition of GPCR Therapeutics USA.
Which conditions is Exicure targeting with Early-Stage?
Early-Stage Biopharmaceutical Operations Exicure is rebuilding a research and development business following the acquisition of GPCR Therapeutics USA. The company has limited liquidity and is simultaneously evaluating financing and strategic alternatives. Stem-Cell Mobilization Program Its lead development program is being evaluated for improving stem-cell...
How does Exicure describe recent progress with Early-Stage?
Exicure is largely a legacy and closeout story, so the catalysts are any strategic or asset-resolution update rather than a live development milestone. The market is focused on what remains.
What is Biopharmaceutical?
Early-Stage Biopharmaceutical Operations Exicure is rebuilding a research and development business following the acquisition of GPCR Therapeutics USA.